A63-49 Therapeutic Effect of Adding Inhaled Treprostinil to PDE5 Inhibitors in Patients With PH-ILD: A Series of Two Cases
Abstract
Currently, there is no definitive treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). Therefore, phosphodiesterase-5 inhibitors (PDE5 inhibitors) have been used as palliative treatment for patients with PH-ILD. Recently, inhaled treprostinil has been approved for the treatment of PH-ILD. Here, we present two cases of PH-ILD, in which patients improved with PDE5 inhibitors and exhibited additional therapeutic benefits from inhaled treprostinil.
A 74-year-old female with idiopathic interstitial pneumonia developed dyspnea. Right heart catheterization (RHC) showed a mean pulmonary arterial pressure (mPAP) of 51 mmHg and pulmonary vascular resistance (PVR) of 10.1 WU, consistent with pulmonary hypertension (PH). Four months after starting tadalafil for PH-ILD, RHC revealed a decrease in mPAP to 26 mmHg. Despite this treatment, PVR remained high. Treprostinil was subsequently administered. After she began additional therapy, RHC showed a decrease in mPAP to 18 mmHg, and PVR to 3.9 WU, without side effects such as decreased oxygen saturation (SpO2) and hypotension. Furthermore, additional therapeutic effects were observed on exercise tolerance and hematological findings. The World Health Organization functional class (WHO-FC) improved from class IV to III, the 6-minute walk distance (6 MWD) improved from 75 to 99 m, and NT-proBNP improved from 1245 pg/mL to 638 pg/mL.Case 2: A 73-year-old male with combined pulmonary fibrosis and emphysema…
Read the paper
Related studies
- Antioxidant efficacy and the upregulation of Nrf2-mediated HO-1 expression by (+)-lariciresinol, a lignan isolated from Rubia philippinensis, through the activation of p38
- Anti-influenza virus activity of green tea by-products in vitro and efficacy against influenza virus infection in chickens
- The intratumoral administration of ferucarbotran conjugated with doxorubicin improved therapeutic effect by magnetic hyperthermia combined with pharmacotherapy in a hepatocellular carcinoma model
- Enhanced anticancer efficacy of TRAIL-conjugated and odanacatib-loaded PLGA nanoparticles in TRAIL resistant cancer
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy
- Endogenous Akt Activity Promotes Virus Entry and Predicts Efficacy of Novel Chimeric Orthopoxvirus in Triple-Negative Breast Cancer
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.